Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

CureDuchenne is investing $1 million in Entos Pharmaceuticals to support the development of a new DMD gene therapy.

Genetic testing for hereditary cancer unexpectedly uncovered a case of myelodysplastic syndrome (MDS), highlighting the need ...